Document is current
Any future updates will be listed below
-
Authors
Lu, Xiaolin
Dai, Tao
Chen, Xue
Wu, Bin
Chen, Hui
Wu, Jitao
Yu, Dexin
Ge, Huixin
Li, Jian
Huang, Houbao
Fan, Tiwu
Cheng, Linzhong
Zhang, Xiaoping
Zhang, Xuepei
Yao, Xin
Wei, Junli
Xu, Zhenqiang
Yang, Wenzeng
He, Chaohong
Luo, Jiexin
Guan, Ling
Fu, Bin
Wang, Qilin
Chen, Xiaofeng
Zhang, Yongdong
Shi, Benkang
Zheng, Bin
Wang, Yong
Luo, Hong
Chen, Guoqiang
Wang, Huan
Wang, Quanren
Ye, Dingwei
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 8 April 2025
First Online: 9 May 2025
Declarations
:
: The protocol and all amendments were approved by the Ethical Committee of Fudan University Shanghai Cancer Center (2012228–15 - 2101 A). The study was conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and the local laws and regulations. All patients provided written informed consent.
: Not applicable.
: Bin Zheng and Guoqiang Chen received research grants from Hengrui; Huan Wang and Quanren Wang are employees of Hengrui. The other authors declare no conflicts of interest.
